Wedbush Maintains Outperform on United Therapeutics, Raises Price Target to $307
Portfolio Pulse from richadhand@benzinga.com
Wedbush analyst Liana Moussatos has maintained an 'Outperform' rating on United Therapeutics (NASDAQ:UTHR) and raised the price target from $305 to $307.
August 04, 2023 | 1:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
United Therapeutics' price target has been raised from $305 to $307 by Wedbush, maintaining an 'Outperform' rating.
The raised price target and maintained 'Outperform' rating by Wedbush indicates a positive outlook for United Therapeutics. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100